NERV - Minerva Neurosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-22.42M

Cash

51.8M

Avg Qtr Burn

-4.408M

Short % of Float

0.90%

Insider Ownership

26.18%

Institutional Own.

30.94%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roluperidone (5-HT2A antagonist) Details Central nervous system illness, Mental health, Schizophrenia Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.